EU approves higher dose of Novo's Wegovy

Core Viewpoint - The European Commission has approved a higher dose of Novo Nordisk's weight-loss drug Wegovy, indicating a significant development for the company in the obesity treatment market [1]. Company Summary - Novo Nordisk's Wegovy has received approval for a higher dosage, which may enhance its market competitiveness and address varying patient needs [1]. Industry Summary - The approval of a higher dose of Wegovy reflects ongoing advancements in the pharmaceutical industry, particularly in the area of obesity treatment, which is gaining increasing attention due to rising obesity rates globally [1].